Current:Home > InvestThe FDA approves the first pill specifically intended to treat postpartum depression-InfoLens
The FDA approves the first pill specifically intended to treat postpartum depression
View Date:2024-12-23 11:56:32
WASHINGTON — Federal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
The Food and Drug Administration on Friday granted approval of the drug, Zurzuvae, for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.
"Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings," said Dr. Tiffany Farchione, FDA's director of psychiatric drugs, in a statement.
Postpartum depression affects an estimated 400,000 people a year, and while it often ends on its own within a couple weeks, it can continue for months or even years. Standard treatment includes counseling or antidepressants, which can take weeks to work and don't help everyone.
The new pill is from Sage Therapeutics, which has a similar infused drug that's given intravenously over three days in a medical facility. The FDA approved that drug in 2019, though it isn't widely used because of its $34,000 price tag and the logistics of administering it.
The FDA's pill approval is based on two company studies that showed women who took Zurzuvae had fewer signs of depression over a four- to six-week period when compared with those who received a dummy pill. The benefits, measured using a psychiatric test, appeared within three days for many patients.
Sahar McMahon, 39, had never experienced depression until after the birth of her second daughter in late 2021. She agreed to enroll in a study of the drug, known chemically as zuranolone, after realizing she no longer wanted to spend time with her children.
"I planned my pregnancies, I knew I wanted those kids but I didn't want to interact with them," said McMahon, who lives in New York City. She says her mood and outlook started improving within days of taking the first pills.
"It was a quick transition for me just waking up and starting to feel like myself again," she said.
Dr. Kimberly Yonkers of Yale University said the Zurzuvae effect is "strong" and the drug likely will be prescribed for women who haven't responded to antidepressants. She wasn't involved in testing the drug.
Still, she said, the FDA should have required Sage to submit more follow-up data on how women fared after additional months.
"The problem is we don't know what happens after 45 days," said Yonkers, a psychiatrist who specializes in postpartum depression. "It could be that people are well or it could be that they relapse."
Sage did not immediately announce how it would price the pill, and Yonkers said that'll be a key factor in how widely its prescribed.
Side effects with the new drug are milder than the IV version, and include drowsiness and dizziness. The drug was co-developed with fellow Massachusetts pharmaceutical company Biogen.
Both the pill and IV forms mimic a derivative of progesterone, the naturally occurring female hormone needed to maintain a pregnancy. Levels of the hormone can plunge after childbirth.
Sage's drugs are part of an emerging class of medications dubbed neurosteroids. These stimulate a different brain pathway than older antidepressants that target serotonin, the chemical linked to mood and emotions.
veryGood! (23)
Related
- 3 Iraqis tortured at Abu Ghraib win $42M judgement against defense contractor
- Child dies after accidental self-inflicted gunshot wound in Georgia store parking lot: reports
- Christine Brown Shares Message About Finding Courage After Kody Brown Split
- Johns Hopkins medical school will be free for most thanks to $1 billion from Bloomberg Philanthropies
- Larry Hobbs, who guided AP’s coverage of Florida news for decades, has died at 83
- Review of prescribed fires finds gaps in key areas as US Forest Service looks to improve safety
- David Byrne: Why radio should pay singers like Beyoncé and Willie Nelson
- Who is Emma Navarro? Meet the American who advanced to the Wimbledon quarterfinals
- Trading wands for whisks, new Harry Potter cooking show brings mess and magic
- Opponents of Louisiana’s Ten Commandments law want judge to block it before new school year starts
Ranking
- Shaun White Reveals How He and Fiancée Nina Dobrev Overcome Struggles in Their Relationship
- Alice Munro's daughter alleges she was abused by stepfather and her mom stayed with him
- New Jersey forest fire that was sparked by fireworks is 75% contained
- North Carolina governor signs 12 bills still left on his desk, vetoes 1 more
- Padma Lakshmi, John Boyega, Hunter Schafer star in Pirelli's 2025 calendar: See the photos
- Full transcript of Face the Nation, July 7, 2024
- Julia Fox Comes Out as Lesbian
- John Cena Announces Retirement From WWE
Recommendation
-
Five best fits for Alex Bregman: Will Astros homegrown star leave as free agent?
-
David Byrne: Why radio should pay singers like Beyoncé and Willie Nelson
-
John Cena announces pending retirement from WWE competition in 2025
-
Glen Powell's Thirst Trap Photo Will Make You Sweat
-
Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Something Corporate
-
Moderate Masoud Pezeshkian wins Iran's presidential runoff election
-
Touring a wasteland in Gaza
-
Don't Wait! You Can Still Shop J.Crew Factory's Extra 70% off Sale with Deals Starting at $6